{"id":"https://openalex.org/W4282919273","doi":"https://doi.org/10.1001/jamanetworkopen.2022.16199","title":"Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma","display_name":"Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma","alternate_titles":[],"publication_year":2022,"publication_date":"2022-06-08","ids":{"openalex":"https://openalex.org/W4282919273","doi":"https://doi.org/10.1001/jamanetworkopen.2022.16199","pmid":"https://pubmed.ncbi.nlm.nih.gov/35675073","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9178436"},"language":"en","primary_location":{"id":"doi:10.1001/jamanetworkopen.2022.16199","doi":"https://doi.org/10.1001/jamanetworkopen.2022.16199","is_oa":true,"landing_page_url":"https://doi.org/10.1001/jamanetworkopen.2022.16199","pdf_url":"https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2793152/kleinbrill_2022_oi_220472_1654027880.97462.pdf","source":{"id":"https://openalex.org/S4210217848","display_name":"JAMA Network Open","issn_l":"2574-3805","issn":["2574-3805"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Network Open","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4282919273"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2793152/kleinbrill_2022_oi_220472_1654027880.97462.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008076450","display_name":"Avital Klein-Brill","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Avital Klein-Brill","raw_affiliation_strings":["Anthem Innovation Israel, Ltd, Tel Aviv, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthem Innovation Israel, Ltd, Tel Aviv, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017206938","display_name":"Shlomit Amar-Farkash","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shlomit Amar-Farkash","raw_affiliation_strings":["Anthem Innovation Israel, Ltd, Tel Aviv, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthem Innovation Israel, Ltd, Tel Aviv, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110648438","display_name":"Gabriella M. Lawrence","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gabriella Lawrence","raw_affiliation_strings":["Anthem Innovation Israel, Ltd, Tel Aviv, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthem Innovation Israel, Ltd, Tel Aviv, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101642291","display_name":"Eric Andrew Collisson","orcid":"https://orcid.org/0000-0002-2829-355X","observed_orcids":["https://orcid.org/0000-0002-2829-355X"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Eric A. Collisson","raw_affiliation_strings":["Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043515714","display_name":"Dvir Aran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I174306211","display_name":"Technion \u2013 Israel Institute of Technology","ror":"https://ror.org/03qryx823","country_code":"IL","type":"education","lineage":["https://openalex.org/I174306211"]}],"countries":["IL"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Dvir Aran","raw_affiliation_strings":["Anthem Innovation Israel, Ltd, Tel Aviv, Israel","Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel","Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion-Israel Institute of Technology, Haifa, Israel","The Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anthem Innovation Israel, Ltd, Tel Aviv, Israel","institution_ids":[]},{"raw_affiliation_string":"Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel","institution_ids":["https://openalex.org/I174306211"]},{"raw_affiliation_string":"Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion-Israel Institute of Technology, Haifa, Israel","institution_ids":["https://openalex.org/I174306211"]},{"raw_affiliation_string":"The Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel","institution_ids":["https://openalex.org/I174306211"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5043515714"],"corresponding_institution_ids":["https://openalex.org/I174306211"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":8.2452,"has_fulltext":true,"cited_by_count":110,"citation_normalized_percentile":{"value":0.98680884,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"5","issue":"6","first_page":"e2216199","last_page":"e2216199"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10760","display_name":"Pancreatitis Pathology and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-pancreatic-ductal-adenocarcinoma","display_name":"metastatic pancreatic ductal adenocarcinoma","score":0.9480000138282776},{"id":"https://openalex.org/keywords/folfirinox","display_name":"FOLFIRINOX","score":0.9919999837875366},{"id":"https://openalex.org/keywords/gemcitabine-plus-nab-paclitaxel","display_name":"gemcitabine plus nab-paclitaxel","score":0.9750000238418579},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.9929999709129333},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8479999899864197},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.5569999814033508},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.7609999775886536},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.597000002861023},{"id":"https://openalex.org/keywords/commercially-insured-patients","display_name":"commercially insured patients","score":0.6110000014305115},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.6240000128746033},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.9409999847412109},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.7639999985694885},{"id":"https://openalex.org/keywords/leucovorin","display_name":"leucovorin","score":0.7919999957084656},{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.7860000133514404}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9020620584487915},{"id":"https://openalex.org/C2777148230","wikidata":"https://www.wikidata.org/wiki/Q17144959","display_name":"FOLFIRINOX","level":5,"score":0.8125190734863281},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6617642641067505},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.6348249912261963},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5997907519340515},{"id":"https://openalex.org/C2779804826","wikidata":"https://www.wikidata.org/wiki/Q45435667","display_name":"Folinic acid","level":4,"score":0.5028979182243347},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.43829184770584106},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.4129314422607422},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3163478374481201},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.281518816947937},{"id":"https://openalex.org/C2780456651","wikidata":"https://www.wikidata.org/wiki/Q238512","display_name":"Fluorouracil","level":3,"score":0.27236106991767883},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.1503334641456604}],"mesh":[{"descriptor_ui":"D000077146","descriptor_name":"Irinotecan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077150","descriptor_name":"Oxaliplatin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000093542","descriptor_name":"Gemcitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000230","descriptor_name":"Adenocarcinoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000230","descriptor_name":"Adenocarcinoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D000418","descriptor_name":"Albumins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002955","descriptor_name":"Leucovorin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1001/jamanetworkopen.2022.16199","doi":"https://doi.org/10.1001/jamanetworkopen.2022.16199","is_oa":true,"landing_page_url":"https://doi.org/10.1001/jamanetworkopen.2022.16199","pdf_url":"https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2793152/kleinbrill_2022_oi_220472_1654027880.97462.pdf","source":{"id":"https://openalex.org/S4210217848","display_name":"JAMA Network Open","issn_l":"2574-3805","issn":["2574-3805"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Network Open","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9178436","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9178436/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Netw Open","raw_type":"Text"},{"id":"pmid:35675073","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35675073","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA network open","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1001/jamanetworkopen.2022.16199","doi":"https://doi.org/10.1001/jamanetworkopen.2022.16199","is_oa":true,"landing_page_url":"https://doi.org/10.1001/jamanetworkopen.2022.16199","pdf_url":"https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2793152/kleinbrill_2022_oi_220472_1654027880.97462.pdf","source":{"id":"https://openalex.org/S4210217848","display_name":"JAMA Network Open","issn_l":"2574-3805","issn":["2574-3805"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Network Open","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G1322387528","display_name":"The structural and functional basis of MET exon 14 activation and acquired drug resistance","funder_award_id":"R01CA230263","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3710616777","display_name":"Crucial Microenvironmental Cofactors for Pancreatic Cancer Pathogenesis","funder_award_id":"R01CA178015","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3935086271","display_name":"Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14","funder_award_id":"R01CA239604","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G80772632","display_name":"Visualization hub for genomics data exploration and translational discovery","funder_award_id":"U24CA210974","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G86018870","display_name":"Tailoring Therapy to Pancreatic Cancer Subtypes","funder_award_id":"R01CA222862","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000904300","display_name":"BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)","funder_award_id":"U54CA224081","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G979293041","display_name":"Genomics and Functional Characterization of NF1-mutated Lung Cancer","funder_award_id":"R01CA227807","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307771","display_name":"Bayer","ror":"https://ror.org/04hmn8g73"},{"id":"https://openalex.org/F4320311647","display_name":"Merck KGaA","ror":"https://ror.org/04b2dty93"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4282919273.pdf","grobid_xml":"https://content.openalex.org/works/W4282919273.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1963697247","https://openalex.org/W1973005031","https://openalex.org/W1994053739","https://openalex.org/W2115275439","https://openalex.org/W2115658806","https://openalex.org/W2131204916","https://openalex.org/W2151253787","https://openalex.org/W2152849583","https://openalex.org/W2565017937","https://openalex.org/W2599017064","https://openalex.org/W2747277320","https://openalex.org/W2768512891","https://openalex.org/W2884529066","https://openalex.org/W2885447570","https://openalex.org/W2928824372","https://openalex.org/W2947566491","https://openalex.org/W2988728533","https://openalex.org/W3126239108","https://openalex.org/W3158634056","https://openalex.org/W3161080579","https://openalex.org/W4205565809","https://openalex.org/W4212867045","https://openalex.org/W4237339613","https://openalex.org/W4246807290","https://openalex.org/W4249999102","https://openalex.org/W4255687048"],"related_works":["https://openalex.org/W4281779225","https://openalex.org/W7162694471","https://openalex.org/W4281396000","https://openalex.org/W2791279584","https://openalex.org/W3158634056","https://openalex.org/W3211337661","https://openalex.org/W4205698152","https://openalex.org/W2890376061","https://openalex.org/W2115275439","https://openalex.org/W2606873218"],"abstract_inverted_index":{"Importance:":[0],"FOLFIRINOX":[1,53,192,249,277,334,389,433],"(leucovorin":[2],"calcium":[3],"[folinic":[4],"acid],":[5],"fluorouracil,":[6],"irinotecan":[7],"hydrochloride,":[8],"and":[9,11,39,54,64,73,80,99,111,124,150,159,171,175,199,205,208,225,304,325,335,358,372,381,404,426],"oxaliplatin)":[10],"gemcitabine":[12,55,194,284,336,401,436],"plus":[13,56,195,285,337,402,437],"nab-paclitaxel":[14,57,286,403],"are":[15,47,68],"the":[16,25,52,91,121,127,185,230,235,276,283,317,424],"2":[17,397],"common":[18],"first-line":[19,418],"therapies":[20],"for":[21,113,135,330],"metastatic":[22,359],"adenocarcinoma":[23],"of":[24,59,103,126,161,189,222,273,395,432],"pancreas":[26],"(mPC),":[27],"but":[28],"they":[29],"have":[30],"not":[31],"been":[32],"directly":[33],"compared":[34,399,434],"in":[35,61,70,117,184,234,275,282],"a":[36],"clinical":[37,41,62,414],"trial,":[38],"comparative":[40,85,385],"data":[42,63,89],"analyses":[43],"on":[44],"their":[45],"effectiveness":[46,86,386],"limited.":[48],"Objective:":[49],"To":[50],"compare":[51],"treatments":[58,128,419],"mPC":[60,165],"evaluate":[65],"whether":[66],"there":[67],"differences":[69],"overall":[71,203,319],"survival":[72,204,211,320,344,394,425],"posttreatment":[74,206,367,375,410,427],"complications":[75],"between":[76,167],"them.":[77],"Design,":[78],"Setting,":[79],"Participants:":[81],"This":[82,343],"retrospective,":[83],"nonrandomized":[84],"study":[87],"used":[88],"from":[90,100],"AIM":[92],"Specialty":[93],"Health-Anthem":[94],"Cancer":[95],"Care":[96],"Quality":[97],"Program":[98],"administrative":[101],"claims":[102],"commercially":[104],"insured":[105],"patients,":[106],"spanning":[107],"388":[108],"outpatient":[109],"centers":[110],"clinics":[112],"medical":[114],"oncology":[115],"located":[116],"44":[118],"states":[119],"across":[120],"US.":[122],"Effectiveness":[123],"safety":[125],"were":[129,182,202,250],"analyzed":[130],"by":[131],"matching":[132],"or":[133,156,193],"adjusting":[134],"age,":[136,241,253],"Charlson":[137,294],"Comorbidity":[138,295],"Index,":[139,296],"ECOG":[140,353],"performance":[141],"status":[142],"(PS)":[143],"score,":[144],"Social":[145],"Deprivation":[146],"Index":[147],"(SDI),":[148],"liver":[149],"lymph":[151],"node":[152],"metastasis,":[153],"prior":[154],"radiotherapy":[155],"surgical":[157],"procedures,":[158],"year":[160],"treatment.":[162],"Patients":[163],"with":[164,191,219,248,265,271,333,392,400,408,435],"treated":[166,247,332],"January":[168],"1,":[169],"2016,":[170],"December":[172],"31,":[173],"2019,":[174],"followed":[176],"up":[177],"until":[178],"June":[179],"30,":[180],"2020,":[181],"included":[183,233],"analysis.":[186],"Interventions:":[187],"Initiation":[188],"treatment":[190,223],"nab-paclitaxel.":[196,438],"Main":[197],"Outcomes":[198,201],"Measures:":[200],"costs":[207,376],"hospitalization.":[209],"Median":[210],"time":[212],"was":[213,321,346,390,405],"calculated":[214],"using":[215],"Kaplan-Meier":[216],"estimates":[217],"adjusted":[218],"inverse":[220],"probability":[221],"weighting":[224],"1:1":[226],"matching.":[227],"Results:":[228],"Among":[229],"1102":[231],"patients":[232,331,362],"analysis":[236],"(618":[237],"men":[238],"[56.1%];":[239],"median":[240,318],"60.0":[242],"[IQR,":[243,255,259,298,302,309,313],"55.5-63.7]":[244],"years),":[245],"those":[246],"younger":[251],"(median":[252,293],"59.1":[254],"53.9-63.3]":[256],"vs":[257,279,300,311],"61.2":[258],"57.2-64.3]":[260],"years;":[261],"P":[262,288],"<":[263,341,378],".001),":[264],"better":[266],"PS":[267,272,354],"scores":[268],"(226":[269],"[39.9%]":[270],"0":[274],"group":[278],"176":[280],"[32.8%]":[281],"group;":[287],"=":[289,370],".02),":[290],"fewer":[291,366,409],"comorbidities":[292],"0.0":[297],"0.0-1.0]":[299],"1.0":[301],"0.0-1.0]),":[303],"lower":[305,374],"SDI":[306],"(median,":[307],"36.0":[308],"16.2-61.0]":[310],"42.0":[312],"23.8-66.2]).":[314],"After":[315],"adjustments,":[316],"9.27":[322],"(IQR,":[323,327],"8.74-9.76)":[324],"6.87":[326],"6.41-7.66)":[328],"months":[329,398],"nab-paclitaxel,":[338],"respectively":[339],"(P":[340,369,377],".001).":[342,379],"benefit":[345,431],"observed":[347],"among":[348],"all":[349],"subgroups,":[350],"including":[351],"different":[352],"scores,":[355],"ages,":[356],"SDIs,":[357],"sites.":[360],"FOLFIRINOX-treated":[361],"also":[363,406],"had":[364],"17.3%":[365],"hospitalizations":[368],".03)":[371],"20%":[373],"Conclusions":[380],"Relevance:":[382],"In":[383],"this":[384],"cohort":[387],"study,":[388],"associated":[391,407],"improved":[393],"approximately":[396],"complications.":[411],"A":[412],"randomized":[413],"trial":[415],"comparing":[416],"these":[417],"is":[420],"warranted":[421],"to":[422],"test":[423],"hospitalization":[428],"(or":[429],"complications)":[430]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4282919273","counts_by_year":[{"year":2026,"cited_by_count":28},{"year":2025,"cited_by_count":32},{"year":2024,"cited_by_count":32},{"year":2023,"cited_by_count":18}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2022-06-16T00:00:00"}
